6 questions answered from cited research · Plain language
Yes, hepatic steatosis can significantly reduce the accuracy of noninvasive fibrosis staging tools like APRI and FIB-4 in chronic hepatitis B patients.
Read the full answer →Pegylated interferon-alpha for chronic hepatitis B commonly causes flu-like symptoms, bone marrow suppression, depression, and autoimmune reactions, often leading to dose adjustments.
Read the full answer →Yes, a liver transplant from a donor with HBV can transmit the virus, but the risk is low (about 4%) and can be reduced with antiviral drugs and vaccination.
Read the full answer →Yes, active HBV infection can increase the risk of liver surgery failure, mainly due to higher chances of viral reactivation and liver damage, but antiviral therapy significantly lowers this risk.
Read the full answer →Immune checkpoint inhibitors appear safe for HBV patients with solid tumors when viral load is suppressed, but reactivation risk exists, especially during immunosuppression for immune-related adverse events.
Read the full answer →NHANES data show that among US adults, past or present Hepatitis B infection is more common in Black adults and those born outside the US compared to White adults or those born in the US.
Read the full answer →